Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Portfolio Pulse from Avi Kapoor
Johnson & Johnson (JNJ) is anticipated to report higher Q1 earnings with an EPS of $2.64, up from $2.41 year-over-year, but with a projected revenue decline to $21.40 billion from $24.75 billion. The company has also entered a collaboration with Rallybio to develop treatments for FNAIT. Analysts have provided mixed ratings and price target adjustments, with the most recent being an Overweight rating and a $215 price target by Cantor Fitzgerald.
April 16, 2024 | 6:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson is expected to report increased Q1 earnings with an EPS of $2.64, despite a revenue decrease. The company's collaboration with Rallybio and recent analyst ratings suggest a positive outlook.
The expected increase in earnings per share (EPS) indicates a positive financial performance, which is typically a bullish signal for investors. The collaboration with Rallybio could open new avenues for growth, further supporting a positive outlook. However, the projected revenue decline might temper some of the enthusiasm. Analyst ratings and price target adjustments reflect a mixed but generally optimistic view, which could influence investor sentiment and stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100